BioCryst Pharmaceuticals
BCRX
BCRX
235 hedge funds and large institutions have $1.08B invested in BioCryst Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 84 increasing their positions, 76 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
4.85% less ownership
Funds ownership: 92.75% → 87.89% (-4.9%)
13% less capital invested
Capital invested by funds: $1.24B → $1.08B (-$166M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Holders
235
Holding in Top 10
5
Calls
$22.1M
Puts
$9.05M
Top Buyers
| 1 | +$26.6M | |
| 2 | +$14.2M | |
| 3 | +$13.8M | |
| 4 |
BlackRock
New York
|
+$11.4M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$9.36M |
Top Sellers
| 1 | -$25M | |
| 2 | -$19.8M | |
| 3 | -$19.5M | |
| 4 |
BNP Paribas Asset Management
Paris,
France
|
-$16.9M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$15.5M |